/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

N

Nobuyuki Yamamoto

Wakayama Medical University(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

1.0K

Papers

29.2K

Citations

73

h-index

349

i10-index

Nobuyuki Yamamoto is an academic researcher from Wakayama Medical University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 73, co-authored 890 publications.

ORCID: 0000-0002-7342-0853

Research Topics

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers

Papers by this author

works

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 · The Lancet Oncology · 747 citations

https://doi.org/10.1016/s1470-2045(14)70381-x

Takashi Seto Terufumi Kato Makoto Nishio Kōichi Goto

Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF

2008 · Translational Oncology · 78 citations

https://doi.org/10.1593/tlo.08106

Nobuto Yamamoto H Suyama Nobuyuki Yamamoto

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

2022 · ESMO Open · 73 citations

https://doi.org/10.1016/j.esmoop.2022.100527

Katsuyuki Hotta Toyoaki Hida Hiroshi Nokihara Masahiro Morise

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

2012 · Investigational New Drugs · 63 citations

https://doi.org/10.1007/s10637-011-9789-z

Toshiaki Takahashi Narikazu Boku Haruyasu Murakami Tateaki Naito

Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study

2017 · BMC Cancer · 63 citations

https://doi.org/10.1186/s12885-017-3795-2

Tateaki Naito Taro Okayama Takashi Aoyama Takuya Ohashi

Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors

2009 · Japanese Journal of Clinical Oncology · 62 citations

https://doi.org/10.1093/jjco/hyp006

Nobuyuki Yamamoto Yasuhide Yamada Yutaka Fujiwara K Yamada

Research topics

topics

Lung Cancer Treatments and Mutations

Lung Cancer Research Studies

Lung Cancer Diagnosis and Treatment

Colorectal Cancer Treatments and Studies

Cancer Immunotherapy and Biomarkers

Chat about Author

Papers

Chat

Click to start Chat